Method for treating endometriosis

HK40137448APending Publication Date: 2026-09-11FLAVISET GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125881
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-16
Filing Date
2026-07-08
Publication Date
2026-09-11
Patent Text Reader

Abstract

The present invention relates to methods of treating endometriosis or preventing recurrence of endometriosis. In particular, the present invention relates to a method of treating endometriosis and relapse thereof, comprising administering to a woman suffering from endometriosis a pharmaceutical composition comprising an S-alkyl isothiourea derivative, in particular S-ethyl isothiourea diethyl phosphate. The methods and pharmaceutical compositions of the present invention can retain fertility and can be fertilized.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480052641.3 (22) Application Date 2024.08.06 (30) Priority Data 63 / 519,855 2023.08.16 US (85) PCT International Application Entering National Phase Date 2026.02.11 (86) PCT International Application Application Data PCT / IL2024 / 050785 2024.08.06 (87) PCT International Application Publication Data WO2025 / 037299 EN 2025.02.20 (71) Applicant: Flaviset Ltd. Address: Jerusalem, Israel (72) Inventor: Rafael Bakkan (74) Patent Agency: Beijing Ruiyang United Intellectual Property Agency Co., Ltd. 11758 Patent Attorney Wang Yuning (51) Int.Cl. A61K 31 / 155 (2006.01) A61K 31 / 27 (2006.01) A61K 31 / 66 (2006.01) A61P 15 / 02 (2006.01) (54) Invention Title: Method for Treating Endometriosis (57) Abstract: This invention relates to a method for treating endometriosis or preventing recurrence of endometriosis. In particular, this invention relates to a method for treating endometriosis and its recurrence, comprising administering a pharmaceutical composition to a woman suffering from endometriosis, the pharmaceutical composition comprising an S-alkyl isothiourea derivative, particularly S-ethyl isothiourea diethyl phosphate. The method and pharmaceutical composition of this invention preserve fertility and enable conception. Claims (3 pages), Description (12 pages), CN 121712498 A, 2026.03.20, CN 1 21 71 24 98 A. 1. A method for treating endometriosis or preventing recurrence of endometriosis, the method comprising administering a therapeutically effective amount of a pharmaceutical composition to a woman requiring the treatment, the pharmaceutical composition comprising a compound of formula I as an active agent: wherein R” is a straight-chain or branched alkyl group, optionally substituted with a halogen; and A”” is an anion derived from a phosphorus-containing acid, phosphate ester, or phosphoramide. 2. The method according to claim 1, wherein A””” is an anion derived from a monoalkyl or dialkyl ester of phosphoric acid or phosphorous acid.3. The method of claim 1, wherein the compound is selected from S-methylisothiourea methyl phosphite; S-methylisothiourea dimethyl phosphate; S-ethylisothiourea metaphosphate; S-ethylisothiourea ethyl phosphite; S-ethylisothiourea diethyl phosphate; S-propylisothiourea propyl phosphite; S-isopropylisothiourea metaphosphate; S-isopropylisothiourea isopropyl phosphite; S-butylisothiourea dibutyl phosphate; and S-isobutylisothiourea isobutyl phosphite. 4. The method of claim 3, wherein the compound is S-ethylisothiourea diethyl phosphate. 5. The method of any one of claims 1 to 4, wherein the endometriosis is selected from ectopic endometriosis, endometrioma, adenomyosis, endometriotic nodules on the uterosacral ligament, and other endometriotic nodules besides those on the uterosacral ligament. 6. The method of any one of claims 1 to 5, wherein the pharmaceutical composition is administered via a route selected from oral administration, vaginal administration, cervical administration, intrauterine administration, intraperitoneal administration, and intralesional administration. 7. The method of claim 6, wherein the pharmaceutical composition is administered via an oral administration route. 8. The method of any one of claims 1 to 7, wherein the pharmaceutical composition is formulated in a form selected from tablets, capsules, solutions, suspensions, emulsions, powders, liquids, gels, syrups, pastes, powders, vaginal suppositories, vaginal rings, vaginal pessaries, vaginal tampons, implants, medicated intrauterine devices, sprays, creams, gels, ointments, and sustained-release formulations. 9. The method of any one of claims 1 to 8, wherein the pharmaceutical composition is administered daily before menstruation, during menstruation, or both. 10. The method of claim 9, wherein the pharmaceutical composition is administered daily 2 to 7 days before menstruation and during menstruation. 11. The method of claim 9, wherein the pharmaceutical composition is administered daily 2 days before menstruation and during menstruation. 12. The method according to any one of claims 1 to 8, wherein the pharmaceutical composition is administered daily for 11 to 17 consecutive days beginning on day 18 to day 23 of the menstrual cycle. 13. The method according to any one of claims 1 to 8, wherein the pharmaceutical composition is administered daily from day 21 of the menstrual cycle and during menstruation. (Claims 1 / 3 page 2 CN 121712498 A) 14. The method according to any one of claims 1 to 8, wherein the pharmaceutical composition is administered daily for 14 consecutive days. 15. The method according to any one of claims 1 to 8, wherein the pharmaceutical composition is administered daily after laparoscopic surgery or endometriosis removal to prevent recurrence of endometriosis.16. The method according to any one of claims 1 to 8, wherein the administration of the pharmaceutical composition prevents or reduces endometrial cell proliferation, migration, and / or infiltration into external uterine sites. 17. The method according to any one of claims 1 to 8, wherein the administration of the pharmaceutical composition prevents or reduces endometrial cell proliferation, migration, and / or infiltration into the uterine wall (myometrium). 18. The method according to any one of claims 1 to 17, wherein the therapeutically effective amount of the compound ranges from 1 mg to 400 mg daily. 19. The method according to claim 18, wherein the therapeutically effective amount is from 50 mg to 100 mg daily. 20. A pharmaceutical composition comprising a compound of formula I as an active agent: wherein R" is a straight-chain or branched alkyl group, optionally substituted with a halogen; and A"(-) is an anion derived from a phosphorus-containing acid, phosphate ester, or phosphoramide, the pharmaceutical composition being used to treat endometriosis or prevent recurrence of endometriosis. 21. The pharmaceutical composition according to claim 20, wherein the anion of the compound of formula I is derived from a monoalkyl or dialkyl ester of phosphoric acid or phosphorous acid. 22. The pharmaceutical composition of claim 20, wherein the compound is selected from S-methylisothiourea methyl phosphite; S-methylisothiourea dimethyl phosphate; S-ethylisothiourea metaphosphate; S-ethylisothiourea ethyl phosphite; S-ethylisothiourea diethyl phosphate; S-propylisothiourea propyl phosphite; S-isopropylisothiourea metaphosphate; S-isopropylisothiourea isopropyl phosphite; S-butylisothiourea dibutyl phosphate; and S-isobutylisothiourea isobutyl phosphite. 23. The pharmaceutical composition of claim 22, wherein the compound is S-ethylisothiourea diethyl phosphate. 24. The pharmaceutical composition of claim 20, wherein the endometriosis is selected from ectopic endometriosis, endometrioma, adenomyosis, endometriotic nodules on the uterosacral ligament, and other endometriotic nodules besides those on the uterosacral ligament. 25. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is administered orally, vaginally, cervix, intrauterinely, intraperitoneally, or intralesionally. 26. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is formulated in a form selected from tablets, capsules, solutions, suspensions, emulsions, powders, liquids, gels, syrups, pastes, powders, vaginal suppositories, vaginal rings, vaginal pessaries, vaginal tampons, implants, medicated intrauterine devices, sprays, creams, gels, ointments, and sustained-release formulations. 27. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is administered daily before menstruation, during menstruation, or both.Claims 2 / 3 Page 3 CN 121712498 A 28. The pharmaceutical composition of claim 27, wherein the pharmaceutical composition is administered daily for 2 to 7 days before menstruation and during menstruation. 29. The pharmaceutical composition of any one of claims 20 to 26, wherein the pharmaceutical composition is administered daily for 11 to 17 consecutive days starting from day 18 to day 23 of the menstrual cycle. 30. The pharmaceutical composition of any one of claims 20 to 26, wherein the pharmaceutical composition is administered daily starting from day 21 of the menstrual cycle and during menstruation. 31. The pharmaceutical composition of any one of claims 20 to 26, wherein the pharmaceutical composition is administered daily for 14 consecutive days. 32. The pharmaceutical composition of any one of claims 20 to 26, wherein the pharmaceutical composition is administered daily after laparoscopic surgery or endometriosis removal to prevent recurrence of endometriosis. 33. The pharmaceutical composition of any one of claims 20 to 26, wherein the administration of the pharmaceutical composition prevents or reduces endometrial cell proliferation, migration, and / or infiltration to external uterine sites. 34. The pharmaceutical composition according to any one of claims 20 to 26, wherein the administration of the pharmaceutical composition prevents or reduces the proliferation, migration, and / or infiltration of endometrial cells into the uterine wall (myolipometrium). 35. The pharmaceutical composition according to claim 20, wherein the pharmaceutical composition is administered to a woman in a therapeutically effective amount to treat or prevent recurrence of endometriosis. 36. The pharmaceutical composition according to claim 35, wherein the therapeutically effective amount of the compound ranges from 1 mg to 400 mg daily. 37. The pharmaceutical composition according to claim 35, wherein the therapeutically effective amount is from 50 mg to 100 mg daily. 38. A method for treating a woman with endometriosis while preserving fertility, the method comprising a compound of formula I as an active agent: wherein R” is a straight-chain or branched alkyl group, optionally substituted with a halogen; and A”” is an anion derived from a phosphorus-containing acid, phosphate ester, or phosphamide. Claims 3 / 3 Page 4 CN 121712498 A Method for Treating Endometriosis Technical Field

[0001] This invention relates to a method for treating endometriosis. In particular, this invention relates to a method for treating endometriosis or preventing recurrence of endometriosis, comprising administering a pharmaceutical composition to a woman suffering from endometriosis or recurrence of endometriosis, the pharmaceutical composition comprising an S-alkyl isothiocyanate derivative, particularly S-ethylisothiourea diethyl phosphate. Background Art

[0002] Endometriosis is a common and debilitating disease in women of reproductive age.This disease occurs in approximately 10% of menstruating women, 20%–50% of infertile women, and 50%–60% of women with chronic pelvic pain. It is characterized by the presence of functional ectopic endometrium or endometriotic tissue in extrauterine regions. Similar to normal endometrial tissue, endometriotic lesions also respond to estrogen stimulation, allowing them to grow and differentiate in accordance with hormonal changes throughout the menstrual cycle. There are three main subtypes of endometriosis: superficial (peritoneal), deep, and ovarian endometriosis. Lesions are usually confined to the pelvis and lower abdomen, commonly found in locations such as the ovaries, posterior broad ligament, posterior fornix, uterosacral ligament, large intestine (rectum), ureters, bladder, upper vagina, and cervix. Less commonly, these lesions can occur extra-abdominal, including in the pleura and pericardium, and rarely in distal organs such as the eyes, brain, and fingers. Clinical manifestations of endometriosis include pelvic pain, including menstrual pain and ovulation pain, dyspareunia, and bowel and bladder symptoms. 30%–50% of patients with endometriosis experience low fertility. Endometriosis patients may also experience other complications such as irritable bowel syndrome (IBS), bladder pain syndrome, chronic fatigue, premenstrual syndrome (PMS), and mood changes such as stress and depression.

[0003] Current treatments for endometriosis have many drawbacks.

[0004] Since the late 1950s, combined oral contraceptives have been the primary means of managing endometriosis symptoms. While not curative, oral contraceptives are generally well-tolerated and can relieve major pain symptoms by suppressing the menstrual cycle and downregulating endometriosis lesions. Continuous use of this medication is recommended for patients with endometriosis. Common side effects include irregular vaginal bleeding, fluid retention, bloating, weight gain, increased appetite, nausea, headache, breast tenderness, and depression. A significant drawback is its contraceptive effectiveness, therefore birth control pills are not suitable for women who wish to preserve their fertility.

[0005] Synthetic progesterone (such as progestin / progestogens) prevents ovulation and has been successfully used to treat endometriosis since the mid-1950s. This includes oral progestins, intramuscular injections, and hormonal intrauterine devices. Common side effects of synthetic progesterone include mood changes, bloating, irregular bleeding, breast tenderness, nausea, headache, acne or oily skin, altered libido, fatigue, and weight gain.

[0006] Gonadotropin-releasing hormone (GnRH) agonists and GnRH antagonists induce artificial menopause by blocking estrogen production. However, common side effects include hot flashes, vaginal dryness, and decreased libido. Long-term use can lead to bone loss, resulting in osteoporosis, and can affect cardiac function.

[0007] Surgical intervention can be performed via laparoscopic minimally invasive surgery.The surgery includes removing endometrial lesions, separating adhesions, removing or ablating endometriotic ovarian cysts, and examining and testing fallopian tube patency. In cases of deep endometriosis involving the intestines, bladder, or ureters, extensive surgery may be required. This may involve intestinal resection, partial bladder removal (partial cystectomy), ureter reimplantation into the bladder, or reanastomosis of the distal ureter (reconnection).

[0008] Symptoms usually improve after surgery, but over time, the lesions may recur in the manner initially described in the specification 1 / 12 page 5 CN 121712498 A. Therefore, hormone therapy is often recommended to prevent recurrence.

[0009] U.S. Patent No. 7,148,208 to Barkan et al. discloses a method for treating headaches and migraines, as well as nausea and vomiting, comprising administering a composition containing an S-alkylisothiourea derivative to a subject requiring such treatment.

[0010] WO2007 / 029255, by one of the inventors of this invention, discloses a method for preventing and stabilizing low blood pressure in hemodialysis patients, comprising administering to these patients a pharmaceutical composition comprising an S-alkylisothiourea derivative.

[0011] WO2007 / 108004, by one of the inventors of this invention, discloses a method for treating inflammation, comprising administering to a subject requiring such treatment a pharmaceutical composition comprising an S-alkylisothiourea derivative.

[0012] WO2009 / 060451, by one of the inventors of this invention, discloses a method for treating excessive uterine contractions, particularly abnormal uterine bleeding and dysmenorrhea, comprising administering to women suffering from such conditions a pharmaceutical composition comprising an S-alkylisothiourea derivative.

[0013] There remains a need for improved methods for treating endometriosis in order to preserve fertility and with negligible side effects compared to currently used medications for treating endometriosis.

[0014] The present invention provides a method for treating endometriosis, comprising administering a pharmaceutical composition comprising an S-alkylisothiourea derivative to a woman in need.

[0015] It is now disclosed for the first time that administering a pharmaceutical composition comprising S-ethylisothiourea diethyl phosphate as an active agent to a woman with endometriosis can reduce the number and / or size of endometrial lesions. Advantageously, treatment of endometriosis with S-ethylisothiourea diethyl phosphate does not adversely affect the patient's hormonal status and preserves the fertility of the woman receiving treatment.

[0016] It is further disclosed that women with endometriosis who receive treatment with a pharmaceutical composition comprising S-ethylisothiourea diethyl phosphate immediately after undergoing a small-incision laparoscopic procedure to remove endometrial tissue from the peritoneum do not experience endometriosis recurrence or have a significantly reduced recurrence rate.

[0017] It is further disclosed that, compared with known drugs, pharmaceutical compositions containing S-ethylisothiourea diethyl phosphate preserve fertility, reduce the number and / or size of endometrial lesions, prevent lesion recurrence, and have negligible or no side effects. Women treated with the pharmaceutical composition are able to conceive during treatment. Furthermore, the pharmaceutical composition does not induce menopausal symptoms.

[0018] It is further disclosed that an ongoing clinical trial protocol aims to test the use of S-ethylisothiourea diethyl phosphate in patients diagnosed with endometriosis. This is the first time it has been disclosed that, unexpectedly, treatment with S-ethylisothiourea diethyl phosphate not only relieves pain and improves the patient's subjective health, but also reduces the recurrence of endometriosis. In other words, the proliferation, migration, and / or infiltration of endometrial cells into the peritoneum and pelvic organs outside the uterus and into the uterine wall (myophyll). Therefore, the method of the present invention has significant advantages compared with currently used methods and drugs for treating endometriosis.

[0019] According to a first aspect, the present invention provides a method for treating endometriosis or preventing recurrence of endometriosis, the method comprising administering to a woman requiring such treatment a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula I as an active agent: Specification 2 / 12 page 6 CN 121712498 A

[0020] wherein R” is a straight-chain or branched alkyl group, optionally substituted with a halogen; and A””-” is an anion derived from a phosphorus-containing acid, phosphate ester, or phosphoramide.

[0021] According to some embodiments, the anion of the compound of formula I is derived from a monoalkyl or dialkyl ester of phosphoric acid or phosphorous acid.

[0022] According to some embodiments, the compound is selected from the following: S-methylisothiourea methyl phosphite; S-methylisothiourea dimethyl phosphate; S-ethylisothiourea metaphosphate; S-ethylisothiourea ethyl phosphite; S-ethylisothiourea diethyl phosphate; S-propylisothiourea propyl phosphite; S-isopropylisothiourea metaphosphate; S-isopropylisothiourea isopropyl phosphite; S-butylisothiourea dibutyl phosphate; and S-isobutylisothiourea isobutyl phosphite.

[0023] According to one embodiment, the compound is S-ethylisothiourea diethyl phosphate.

[0024] According to some embodiments, endometriosis is selected from ectopic endometriosis, endometrioma, adenomyosis, endometriotic nodules on the uterosacral ligament, and other endometriotic nodules other than those on the uterosacral ligament.

[0025] According to a further embodiment, the pharmaceutical composition is administered via oral administration, vaginal administration, cervical administration, intrauterine administration, intraperitoneal administration, or intralesional administration.According to some embodiments, the pharmaceutical composition is administered via an oral route. According to an exemplary embodiment, the pharmaceutical composition is administered via a vaginal route.

[0026] According to some embodiments, the composition is formulated as tablets, capsules, powders, solutions, suspensions, emulsions, suppositories, implants, or sustained-release formulations.

[0027] According to a further embodiment, the pharmaceutical composition is formulated as tablets, capsules, liquids, gels, syrups, slurries, and suspensions.

[0028] According to yet another embodiment, the pharmaceutical composition is formulated as vaginal suppositories, tampons, vaginal rings, vaginal pessaries, vaginal sponges, medicated intrauterine devices (IUDs), sprays, creams, gels, ointments, sustained-release formulations, tablets, capsules, solutions, suspensions, emulsions, and powders. According to some embodiments, the pharmaceutical composition is formulated as a vaginal suppository or tablet.

[0029] According to a further embodiment, the pharmaceutical composition is administered daily before menstruation, during menstruation, or both before and during menstruation. The application may be performed for one, two, three, four, or five months, or as needed according to the instructions for use in treating endometriosis (page 3 / 12, CN 121712498 A). According to some embodiments, the pharmaceutical composition is administered continuously.

[0030] According to some embodiments, the pharmaceutical composition is administered 2 to 7 days before menstruation and during menstruation. According to one embodiment, the pharmaceutical composition is administered 2 days before menstruation and during menstruation.

[0031] According to some embodiments, the pharmaceutical composition is administered daily for 11 to 17 days, starting from day 18 to day 23 of the first day of menstruation. According to an exemplary embodiment, the pharmaceutical composition is administered on day 21 of the menstrual cycle. According to another exemplary embodiment, the pharmaceutical composition is administered daily for 14 consecutive days.

[0032] According to some embodiments, the pharmaceutical composition is administered once a day, once every two days, once every three days, once a week, once every two weeks, or once a month for a period of time, starting from day 18 to day 23 of the first day of menstruation. Alternative regimens may be adjusted according to the instructions of the physician treating the patient. According to certain embodiments, the pharmaceutical composition is administered multiple times a day, such as twice a day, three times a day, or as needed.

[0033] According to a further embodiment, after laparoscopic surgery or removal of endometriotic tissue, the pharmaceutical composition is administered once a day, once every two days, once every three days, once a week, once every two weeks, or once a month to prevent recurrence of endometriosis.

[0034] According to a further embodiment, after laparoscopic surgery or removal of endometriotic tissue, the pharmaceutical composition is administered once a day, once every two days, once every three days, once a week, once every two weeks, or once a month for at least one month, two months, three months, four months, five months, or at least six months, or for a longer period of time as needed, to prevent recurrence of endometriosis.

[0035] According to some embodiments, the therapeutically effective amount of the compound of formula I ranges from 1 mg to about 400 mg, optionally from 50 mg to about 200 mg, optionally from 30 mg to about 150 mg. According to one embodiment, the therapeutically effective amount of S-ethylisothiourea diethyl phosphate is 100 mg per unit dose. Each possibility represents an independent embodiment of the invention.

[0036] According to some embodiments, administration of the pharmaceutical composition can treat endometriosis. According to other embodiments, administration of the pharmaceutical composition can prevent recurrence of endometriosis. According to a further embodiment, administration of the pharmaceutical composition can prevent endometrial cell proliferation, migration, and / or invasion to external uterine sites. According to certain embodiments, administration of the pharmaceutical composition can reduce endometrial cell proliferation, migration, and / or infiltration into the peritoneum and pelvic organs outside the uterus. According to certain embodiments, administration of the pharmaceutical composition can prevent endometrial cell proliferation, migration, and / or infiltration into the uterine wall (myotomy). According to further embodiments, administration of the pharmaceutical composition can reduce endometrial cell proliferation, migration, and / or infiltration into the peritoneum and pelvic organs. According to further embodiments, administration of the pharmaceutical composition can reduce the size of endometrial lesions. According to some embodiments, administration of the pharmaceutical composition can shrink endometrial lesions.

[0037] According to a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula I as an active agent:

[0038] wherein R” is a straight-chain or branched alkyl group, optionally substituted with a halogen; and A”(-) is an anion derived from a phosphorus-containing acid, phosphate ester, or phosphoramide, for treating endometriosis or preventing recurrence of endometriosis. According to another aspect, the present invention provides a method for treating women suffering from endometriosis while preserving fertility, said method by administering a therapeutically effective amount of a pharmaceutical composition to increase the probability of conception, said pharmaceutical composition comprising a compound of formula I as an active agent:

[0039] wherein R” is a straight-chain or branched alkyl group, optionally substituted with a halogen; and A””-” is an anion derived from a phosphorus-containing acid, phosphate ester, or phosphoramide.

[0040] These and other embodiments of the invention can be better understood in conjunction with the following description, examples, and claims.Detailed Description

[0041] The present invention provides methods for treating endometriosis and / or preventing recurrence of endometriosis and / or endometriotic lesions and / or preserving the fertility of women with endometriosis. These methods include administering a pharmaceutical composition to a woman with endometriosis or at risk of recurrence of endometriosis, the pharmaceutical composition comprising an S-alkylisothiourea derivative as an active agent. The methods and pharmaceutical compositions can preserve the fertility of women with endometriosis, thereby enabling them to conceive during or after treatment.

[0042] The compounds of the present invention, according to the present invention, are S-alkylisothiourea derivatives of formula I:

[0043] wherein R” is a straight-chain or branched alkyl group, optionally substituted with a halogen; and A”” is an anion derived from a phosphorus-containing acid, phosphate ester, or phosphoramide.

[0044] According to some embodiments, the anion is derived from a monoalkyl or dialkyl ester of phosphoric acid or phosphorous acid.

[0045] According to some embodiments, the compound is selected from the following: S-methylisothiourea methyl phosphite; S-methylisothiourea dimethyl phosphate; S-ethylisothiourea metaphosphate; S-ethylisothiourea ethyl phosphite; S-ethylisothiourea diethyl phosphate; S-propylisothiourea propyl phosphite; S-isopropylisothiourea metaphosphate; (See specification 5 / 12 pages 9 CN 121712498) S-isopropylisothiourea isopropyl phosphite; S-butylisothiourea dibutyl phosphate; and S-isobutylisothiourea isobutyl phosphite.

[0046] According to one embodiment, the compound is S-ethylisothiourea diethyl phosphate.

[0047] Pharmaceutical Composition The pharmaceutical compositions of the present invention comprise an S-alkylisothiourea derivative and a pharmaceutically acceptable carrier.

[0048] The term “pharmaceuticalally acceptable” means approved by a federal or state regulatory agency, or listed in the United States Pharmacopeia or other recognized pharmacopoeia, for use in animals, especially humans. The term “carrier” refers to a diluent, adjuvant, excipient, or solvent with which a therapeutic compound is administered. Such drug carriers can be sterile liquids, such as water and oils, including petroleum, animal, plant, or synthetic oils, such as peanut oil, soybean oil, mineral oil, sesame oil, etc., or polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents. For example, water, saline solutions, glucose solutions, and glycerin solutions can be used as liquid carriers, such as liquid carriers for injection. Suitable drug excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, dried skim milk, propylene glycol, water, ethanol, etc. If desired, the composition may also contain small amounts of wetting agents or emulsifiers, or pH buffers, such as acetates, citrates, or phosphates.Antimicrobial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; and agents for regulating tension such as sodium chloride or glucose are also considered.

[0049] The composition may be in the form of tablets, capsules, powders, solutions, suspensions, emulsions, suppositories, implants, sustained-release formulations, etc., depending on the chosen route of administration.

[0050] Suitable routes of administration for practicing the present invention include oral administration, vaginal administration, intrauterine administration, intraperitoneal administration, and intralesional administration.

[0051] For oral administration, the pharmaceutical compositions of the present invention may be formulated as tablets, capsules, liquids, gels, syrups, pastes, suspensions, etc. Suitable excipients, especially fillers, include sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations, such as, for example, corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose; and / or physiologically acceptable polymers, such as polyvinylpyrrolidone (PVP). If desired, disintegrants, such as croscarmellose, agar, or alginate or its salts, such as sodium alginate, may also be added. Examples of suitable drug carriers are described in EW Martin’s “Remington’s Pharmaceutical Sciences.” Such compositions will contain a therapeutically effective amount of an S-alkylisothiourea derivative and an appropriate amount of carrier to provide a form suitable for administration to a subject.

[0052] For oral administration, the composition may be in tablet or lozenge form formulated in a conventional manner.

[0053] For parenteral administration, the pharmaceutical compositions of the present invention may be formulated as an aqueous solution, preferably a physiologically compatible buffer, such as Hank's solution, Ringer's solution, or saline buffer. In addition, suspensions of the active compound can also be prepared as suitable oily injectable suspensions. Suitable lipophilic solvents or media include fatty oils (such as sesame oil) or synthetic fatty acid esters (such as ethyl oleate), triglycerides, or liposomes. Aqueous injectable suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, and / or dextran. Optionally, the suspension may also contain suitable stabilizers or reagents that can increase the solubility of the compound in order to prepare high-concentration solutions. Parenteral formulations may optionally contain one or more additional ingredients, among which preservatives (when the formulation is packaged in multi-dose containers), buffers that provide a suitable pH for the formulation, and sodium chloride or glycerol to make the formulation isotonic with blood may be mentioned.

[0054] The pharmaceutical compositions of the present invention can be formulated into extended-release drug dosage forms known in the art (e.g., see U.S. Patent Nos. 6,605,303; 6,419,958; 6,245,357, the contents of which are incorporated herein by reference as set forth in the complete specification on page 6 / 12 of CN 121712498 A).

[0055] Thus, the extended-release drug dosage forms of the S-alkylisothiourea derivatives of the present invention comprise an S-alkylisothiourea derivative, a polymer, and optionally one or more additional pharmaceutically acceptable excipients or carriers.

[0056] Polymers that can be used to prepare the extended-release drug dosage forms of the present invention include hydrophilic polymers, hydrophobic polymers, and combinations thereof.

[0057] Suitable hydrophilic polymers are, for example, hydroxypropyl methylcellulose, hydroxypropyl cellulose, ethyl hydroxyethyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, methylcellulose, polyethylene oxide, polyvinyl alcohol, tragacanth gum, and xanthan gum. These polymers can be used alone or in mixtures thereof.

[0058] Examples of hydrophobic polymers include polyvinyl chloride, ethyl cellulose, polyvinyl acetate, and acrylic copolymers, such as Eudragith™. The polymers can be used alone or as mixtures. Optionally or additionally, hydrophobic agents can be used as hydrophobic matrices, such as waxes like cetyl alcohol, cetearyl alcohol, cetyl palmitate, carnauba wax, paraffin wax, magnesium stearate, sodium stearoyl fumarate, and medium- or long-chain glycerides, which can be used alone or in any mixture.

[0059] The extended-release drug formulations of the present invention may further comprise binders, such as sugars, polyvinylpyrrolidone, starch, and gelatin; surfactants, such as nonionic surfactants, such as polysorbate 80, or ionic surfactants, such as sodium dodecyl sulfate; lubricants, such as magnesium stearate, sodium stearate fumarate, or hexadecyl palmitate; fillers, such as sodium aluminum silicate, lactose, or calcium phosphate; flow aids, such as talc and aerosols; and antioxidants.

[0060] Formulations can be administered transmucosally in the form of ointments, emulsions, gels, lotions, solutions (such as rinsing solutions), creams, or patches (in the case of transdermal delivery). Suitable drug carriers for transmucosally delivery include, for example, polyethylene glycol, propylene glycol, glycerin, isopropanol, ethanol, oleic acid, N-methylpyrrolidone, sesame oil, olive oil, lignin ointments, petrolatum, and paraffin, or mixtures thereof.

[0061] For transmucosally delivery of gel, cream, or ointment formulations to the vaginal mucosa, carrier compositions based on bioadhesive polymers are particularly useful. Suitable bioadhesive polymers are, for example, those described in U.S. Patent No. 4,615,697, the contents of which are incorporated herein by reference.Particularly useful polymers are cross-linked polycarboxylic acid polymers, which have a sufficiently high degree of cross-linking to impart the desired level of bioadhesion to the target epithelial surface. Representative bioadhesive polymer formulations have been described, for example, in U.S. Patent Nos. 5,543,150 and 5,667,492. Other additives suitable for incorporation into bioadhesive polymer formulations include one or more of preservatives, humectants, lubricants and / or wetting agents, stabilizers, pigments, pH adjusters (such as alkalis), and purified water. Depending on the formulation additives and the resulting viscosity, such formulations can be administered vaginally as douches, using pistons, or formulated as suppositories.

[0062] Vaginal suppositories containing S-alkylisothiourea derivatives can release over an extended period of time and are particularly suitable for the treatment or prevention of endometriosis. Rectal suppositories can also be used to deliver S-alkylisothiourea derivatives. Typical matrix carriers for vaginal or rectal suppositories include, for example, natural, synthetic, or partially synthetic fats, waxes, and their derivatives derived from animal, plant, or mineral sources. Specific examples include olive oil, corn oil, castor oil, hydrogenated oil, petrolatum, solid paraffin, liquid paraffin, carnauba wax, beeswax, lanolin, partially or fully synthetic glycerol fatty acid esters, mono-, di-, or triglycerides of saturated or unsaturated fatty acids, and carriers well known in the art. Other additives suitable for incorporation into the suppositories of the present invention include preservatives, stabilizers, surfactants, pigments, pH adjusters, and purified water known in the art.

[0063] Devices suitable for vaginal or cervical implantation include tampons, vaginal rings, vaginal cups, cervical cups, vaginal pessaries, vaginal sponges, and medicated intrauterine devices (IUDs). Tampons may be impregnated and / or coated with an effective amount of S-alkyl isothiourea derivatives, the duration of which should conform to the safe and hygienic tampon use time (typically changing tampons every 4 to 8 hours). Examples of tampons impregnated or coated with therapeutic agents can be found, for example, in U.S. Patent Nos. 3,995,636, 4,186,742, 4,340,055, 4,582,717, 5,201,326, and 5,417,224, the contents of which are incorporated herein by reference. S-alkylisothiourea derivatives may be incorporated / impregnated into a nonwoven overlay sheet permeable to bodily fluids and superimposed on a first absorbent sheet that, when rolled or shaped into the desired tampon shape, constitutes the tampon body, with the S-alkylisothiourea derivative-containing layer remaining on the outermost surface. Alternatively, the S-alkylisothiourea derivative may also be deposited during manufacturing between the absorbent sheet body and the permeable overlay sheet.Optionally, S-alkylisothiourea derivatives may also be incorporated into tampon sleeves made of hardened collagen or gelatin foam containing slow-release materials, such as triglycerides of higher fatty acids that melt at body temperature, for application to absorbent natural or synthetic tampon cores.

[0064] Another method of manufacturing S-alkylisothiourea derivative-impregnated tampons is to incorporate the S-alkylisothiourea derivative into a suppository matrix formulation, then melt it, inject it into the tampon using a syringe, and allow it to cool. Optionally, a melted suppository formulation containing an active agent may also be coated onto a pre-formed tampon. In either case, the result is that the tampon gradually releases the S-alkylisothiourea derivative as the suppository matrix melts at body temperature. Useful suppository adjuvants are those described above and those described in U.S. Patent No. 4,582,717.

[0065] In vaginal and cervical devices (such as vaginal rings, vaginal cups, cervical cups, vaginal pessaries, vaginal sponges), compounds are incorporated into these devices in the form of creams, washes, foams, solutions, pastes, ointments, or gels.

[0066] IUDs include non-bioerodible, partially bioerodible, and fully bioerodible IUDs. Typically, IUDs are made of a flexible polymeric non-erodible core and are coated with a bioerodible coating material containing an S-alkylisothiourea derivative. Alternatively, the IUD core may also be a bioerodible material containing an S-alkylisothiourea derivative for sustained release and may further include or exclude an active agent release outer coating. The latter configuration eliminates the need to remove the device after all the agent has been released. For example, in practice, the medicated intrauterine device (IUD) may be constructed from a non-biodegradable hydrophobic substrate with high mechanical elasticity, wherein the substrate contains inclusions of polymeric hydrophilic substances within its volume. These inclusions are grafted onto the hydrophobic substrate and cross-linked, and contain S-alkyl isothiourea derivatives that permeate through the hydrophobic substrate when it is placed in an aqueous medium. Suitable materials for the hydrophobic substrate are polymeric thermoplastic products, such as, for example, vinyl acetate, polyethylene, or copolymers of vinyl acetate and polyethylene, or more generally ethylene copolymers, polyethers, polyurethanes, or polyacrylonitrile. Suitable materials for the hydrophilic substances include ethylene glycol acrylate, ethylene glycol methacrylate, acrylamide, methacrylamide, acrylamide methanol, acrylamide diacetone, or unsaturated acidic products such as malic acid, acrylic acid, methacrylic acid, fumaric acid, itaconic acid, or propylene glycol acrylate or methacrylate. In addition, polypropylene, polyamide, polyester (such as ethylene glycol), polyethylene terephthalate, polyvinyl chloride, polyoxymethylene chloride, polycarbonate and polytetrafluoroethylene ("Teflon") can also be used.

[0067] For medicated intrauterine devices that are at least partially bioerodible, the material must be non-toxic and non-irritating to the endometrium, and its bioerodible end products must also be non-toxic and easily expelled from the body.Exemplary biodegradable materials include natural and synthetic materials, such as (a) animal-derived structural proteins and hydrocolloids; (b) plant-derived polysaccharides and other hydrocolloids; and (c) synthetic polymers. Some of these matrix materials are suitable in their natural form, but others (particularly hydrocolloids) require chemical or physical modification (such as directional, radiation crosslinking, etc.) to achieve insolubility. Examples of the first class (natural and modified proteins) include: natural and modified collagen, muscle proteins, elastin, keratin, arthropod elastin, fibrous proteins, etc. Examples of polysaccharides and plant hydrocolloids include: lignin, pectin, carrageenan, chitin, heparin, chondroitin sulfate, agar, guar gum, locust bean gum, gum arabic, ark sylvestris gum, tragacanth gum, gum arabic, starch, oxidized starch, phosphate starch, carboxymethyl starch, sulfoethyl starch, aminoethyl starch, amide ethyl starch, starch esters (such as maleic starch ester, succinic starch ester, benzoic starch ester and acetate starch ester), and mixtures of starch and gelatin; cellulose and its derivatives, such as modified cellulose (such as partially hydroxyethylated cotton obtained by ethylene oxide treatment, or partially carboxymethylated cotton obtained by alkali and chloroacetic acid treatment). Examples of synthetic polymers include poly(vinyl alcohol), poly(ethylene oxide), poly(acrylamide), poly(vinylpyrrolidone), poly(ethyleneimine), poly(vinylimidazolium), poly(phosphate esters), synthetic peptides, polyvinyl alkyl ethers, polyacrylamide, and polymethacrylamide, as well as copolymers of acrylamide and methacrylamide with up to 40 wt% of N-methylenebisacrylamide or N,N-dimethylurea; water-soluble hydrophilic polymers of polyalkylaldehydes, non-crosslinked hydroxyalkyl acrylates and methacrylates, polyalkylene carbonates, etc. Any biocorrosive material that is compatible with S-alkylisothiourea derivatives, non-toxic, and has the desired erosion and release rates can be used. Typically, cross-linking agents (e.g., aldehydes such as acetaldehyde, formaldehyde, acrolein, crotonaldehyde, glutaraldehyde, glyoxal, dihydroxymethylurea, trihydroxymethyl melamine, tetra(methoxymethyl)urea, melamine, epichlorohydrin, and hexamethylenetetramine) and plasticizers (e.g., tributyl acetyl citrate, epoxidized soybean oil, glyceryl monoacetate, polyethylene glycol, propylene glycol dilaurate, decanol, dodecanol, 2-ethylhexanol, 2,2-butoxyethoxyethanol, etc.) are added to impart the desired bio-erosion rate and flexibility to the IUD, respectively. Medicated intrauterine devices include, for example, pessaries, spiral or ring-shaped IUDs, such as the Mirena® ring.

[0068] Use of S-alkyl isothiourea derivatives This invention provides an effective and highly safe method for treating endometriosis in women.These methods involve administering a pharmaceutical composition to women with endometriosis or at risk of recurrent endometriosis, the pharmaceutical composition comprising an S-alkylisothiourea derivative as an active agent.

[0069] As used herein, the term “endometriosis” refers to any non-malignant condition in which functional endometrial tissue is present in a body part outside the uterine cavity. If the endometrial tissue is present within the uterine wall (myolipoma), it is called “adenomyosis” of the uterus. Therefore, the term “endometriosis” includes “endometriosis” as defined in the Merck Manual, which refers to the presence of endometrial tissue outside the uterine cavity, including uterosacral tubercles, endometriomas, adnexal adhesions, and adenomyosis where endometrial tissue is present within the myometrium.

[0070] Therefore, endometriosis includes what is commonly referred to as peritoneal endometriosis, deep invasive endometriosis, ovarian endometriosis, extrauterine endometriosis, endometrioma, endometriosis (adenomyosis), any term including "endometriosis" (e.g., scarred endometriosis), and any non-malignant disease in which functional endometrial tissue is present in a location outside the endometrium.

[0071] As used herein, "endometrial tissue" means endometrial tissue present in endometriosis, i.e., endometrial tissue present in a location outside the endometrium.

[0072] Throughout the specification and claims, the terms "treatment" and "treating" are used interchangeably and refer to the ability to effectively alleviate endometriosis. Therefore, treating or treating endometriosis includes, for example, causing endometrial lesions to regress or disappear. It is understood that the terms “treatment” and “management” include “prevention.” “Prevention” refers to the ability to prevent recurrence of endometriosis.

[0073] As used herein, the term “menstrual cycle” refers to the time from the first day of a woman’s menstrual period (menstruation) to the first day of the next menstrual period.

[0074] Therefore, according to the present invention, the S-alkylisothiourea derivative of the present invention can reduce the number and / or size of endometriotic lesions. Preferably, the S-alkylisothiourea derivative of the present invention can prevent recurrence of endometriosis. Specifically, according to the present invention, the S-alkylisothiourea derivative of the present invention can reduce or eliminate the proliferation, migration, and / or infiltration of endometrial or endometriotic cells into external sites of the uterus and into the uterine wall (myophyll). The S-alkylisothiourea derivative of CN 121712498 A (pages 9 / 12 of this specification) can also alleviate or eliminate symptoms associated with endometriosis, such as infertility. Therefore, the S-alkyl isothiourea derivative of the present invention can improve the fertility of women with endometriosis.According to some embodiments, the S-alkylisothiourea derivative of the present invention can be administered from one to seven days after laparoscopic or surgical removal of endometriotic tissue and terminated within at least one month thereafter. To prevent recurrence of endometriosis, the S-alkylisothiourea derivative of the present invention can be administered once a day, once every two days, once every three days, once a week, once every two weeks, or once a month. To prevent recurrence of endometriosis, the S-alkylisothiourea derivative of the present invention can be administered for one year or longer as needed. To prevent recurrence of endometriosis, the S-alkylisothiourea derivative of the present invention can be administered subsequently as needed. Alternative regimens can be adjusted by the physician treating the patient as needed.

[0075] The pharmaceutical composition of the present invention can be administered via a route of administration selected from oral, vaginal, cervical, intrauterine, intraperitoneal, and intralesional administration.

[0076] As used herein, "intralesional administration" means administration to or within the pathological area. Administration can be performed by injection into the lesion and / or perfusion into an existing cavity (such as an endometrioma). Intralesional application refers to treatment within endometriotic tissue or cysts formed from such tissue, such as injection into the cyst. "Intralesional application" also includes application to tissue very close to the endometriotic tissue, allowing the S-alkylisothiourea derivative to act directly on the endometriotic tissue.

[0077] The invention also includes using a therapeutic dose of the S-alkylisothiourea derivative together with other therapeutic agents to treat or alleviate endometriosis. In methods of co-administering the S-alkylisothiourea derivative with one or more additional therapeutic agents, it is conceivable that all agents may be administered simultaneously or sequentially. Thus, an effective dose of S-alkylisothiourea can be formulated with additional agents into a single composition. Alternatively, if sequential co-administration is more suitable or feasible, separate dosage forms will be used, administered via the same or different routes of administration.

[0078] The compounds suitable for "another therapeutic agent" are those formulations that can be used to alleviate or treat endometriosis. Representative therapeutic agents for treating endometriosis include hormones, such as combination contraceptives, androgens (such as danazol), gonadotropin-releasing hormone (GnRH) analogs, and progestins.

[0079] The pharmaceutical compositions suitable for use in this invention comprise a therapeutically effective amount of the active agent to achieve the intended purpose. More specifically, a “therapeutically effective amount” means an amount of compound effective in preventing, alleviating, or treating endometriosis in a treated woman.

[0080] The determination of a therapeutically effective amount is entirely within the capabilities of those skilled in the art, particularly under the guidance of the disclosure herein.

[0081] The pharmaceutical compositions of this invention can be administered before menstruation, during menstruation, or simultaneously before and during menstruation.Optionally, the pharmaceutical composition may also be administered during the luteal phase of the menstrual cycle.

[0082] As used herein, the term "fertility preservation" refers to a woman's ability to conceive. The non-hormonal treatment for endometriosis provided by the present invention allows / enables female subjects receiving said treatment to conceive during or after treatment. The pharmaceutical compositions of the present invention not only preserve female fertility but also increase the probability of conception.

[0083] The specific formulation, route of administration, and dosage may be selected by an individual physician based on the patient's condition. (See, for example, Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p. 1).

[0084] The amount of composition to be administered will depend on the treated subject, such as weight, age, medical history, severity of disease, route of administration, prescribing physician's judgment, etc.

[0085] Example 1 Instructions for Use 10 / 12 pages 14 CN 121712498 Effect of S-ethylisothiourea diethyl phosphate on female endometriosis To evaluate the effect of S-ethylisothiourea diethyl phosphate on moderate to severe endometriosis lesions in women, 40 women aged 20-50 years with endometriosis participated in the experiment. 20 women were treated with 100 mg of S-ethylisothiourea diethyl phosphate tablets. 20 women were treated with a placebo. Each woman was treated once daily, starting two days before menstruation and for five days during menstruation. Treatment was repeated for three cycles. Women underwent ultrasound examination to assess the size and number of endometrial lesions. In addition, other parameters were assessed, such as menstrual flow and the women's overall health.

[0086] Example 2 Effects of S-ethylisothiourea diethyl phosphate on endometrial cells in women with endometriosis To evaluate the safety and efficacy of RAVISET® (S-ethylisothiourea diethyl phosphate) in treating pain, quality of life, and endometrial lesions in women with endometriosis, a prospective, randomized, double-blind, placebo-controlled, multicenter phase II study was conducted. This study included 74 premenopausal women aged 18 to 49 years who were diagnosed with endometriosis (surgically or clinically) and suffered from moderate to severe pain. Women participating in this study must have regular menstrual cycles with a cycle interval of 24–38 days and a bleeding period of 3–8 days. Women who were pregnant, breastfeeding, or planning to become pregnant within the next 8 months were excluded from this study. Women willing to participate in the clinical study were required to sign an informed consent form. Eligible female participants who have obtained informed consent and meet the inclusion criteria will undergo a screening visit (Visit 1). After the visit, they will be included in the study and assigned to receive either the study product or a placebo.During Visit 1, prior to enrollment, demographic data, general medical history of comorbidities and medications, and specific history of endometriosis were recorded for the subjects.

[0087] The study design included 37 women treated with 100 mg of S-ethylisothiourea diethyl phosphate tablets orally and 37 women treated with a placebo orally. All women underwent a 3-month cleansing period before starting treatment and discontinued any hormone therapy. After the cleansing period, treatment began on day 21 of a single menstrual cycle each month, for 14 consecutive days, for 3 consecutive cycles, after determining the length of the menstrual cycle. Women underwent ultrasound examination to assess the size and number of endometrial lesions. As part of the protocol, women also underwent physical examinations, including recording of vital signs (heart rate (HR), blood pressure (BP), body temperature), and were required to provide pregnancy test results. Routine laboratory blood tests included: complete blood count (CBC), clinical chemistry, and coagulation function. Vaginal pH and urine analysis were also performed.

[0088] To assess the impact of the study treatment on the quality of life of the participants, women were asked to complete the following questionnaires: - Patient Global Impression Questionnaire (PGIC) - 30-item Endometriosis Health Profile (EHP-30), a self-administered questionnaire, and - Endometriosis Health Profile (EQ-5D-5L) questionnaire.

[0089] All participants received an electronic diary at the end of the screening visit (Visit 1) and received training on how to report daily on endometriosis-related pain assessments, use of protocol-prescribed remedial analgesics, and characteristics of uterine bleeding during the cleansing initiation and study treatment periods.

[0090] During the “cleansing initiation” period, participants were required to return for a follow-up visit every 6 weeks and were observed twice, on day 45 (Visit 2) and day 90 (Visit 3) after enrollment. At each “cleansing and induction” visit, subjects underwent a physical examination, including recording of vital signs (HR, BP, temperature), and were required to provide pregnancy test results and be evaluated via transvaginal ultrasound. The Comprehensive Pelvic Signs and Symptoms Score (CPSSS) pain score was assessed by a physician, who also reviewed the patient's daily assessment of endometriosis-related pain, use of rescue analgesics, and uterine bleeding. Subjects were required to complete all study questionnaires and report adverse events and changes in concomitant medications. At the final “cleansing and induction” visit (Visit 3), subjects were given either the investigational drug Raviset® or a placebo tablet, along with detailed instructions for use.

[0091] Once the 3-month “cleansing and induction” period ended and the individual menstrual cycle length was determined, subjects entered the study “treatment period”.During this 3-month period, participants self-administered the study tablets, maintained a daily electronic diary (as described above), and were required to visit the clinic monthly. At each of the monthly visits during the “treatment period” (Visits 4–6), participants underwent a physical examination, including recording of vital signs (HR, BP, temperature), providing pregnancy test results, and undergoing evaluation via transvaginal ultrasound. The CPSSS pain score was assessed by the physician, who also reviewed the patient's daily electronic diary assessments for endometriosis-related pain, use of rescue analgesics, and uterine bleeding. Participants were required to complete all study questionnaires and report adverse events and changes to concomitant medications. Participants were instructed to return used / unused tablet containers at subsequent treatment visits for medication adherence verification. A safety follow-up (FU) telephone visit (Visit 7) was conducted 30 days after the end of treatment (EoT) visit to complete the treatment period. During the safety FU telephone visit, participants were asked about any adverse events and any changes to concomitant medications were recorded. However, if any serious adverse event (SAE) is not resolved, or if abnormalities are observed during transvaginal ultrasound and / or laboratory tests during EoT, the subject is required to attend a safety follow-up (FU) visit at the clinic.

[0092] Although the protocol was intended to confirm pain relief, unexpectedly, S-ethylisothiourea diethyl phosphate (RAVISET®) reduced the recurrence of endometriosis infiltration into the extraperitoneal uterine site.

[0093] Those skilled in the art will recognize that the invention is not limited to what has been specifically shown and described above. Rather, the scope of the invention is defined by the appended claims. Specification 12 / 12 pages 16 CN 121712498 A.

Claims

1. A method for treating endometriosis or preventing recurrence of endometriosis, the method comprising administering a therapeutically effective amount of a pharmaceutical composition to a woman requiring the treatment, the pharmaceutical composition comprising a compound of formula I as an active agent: in R ” It is a straight-chain or branched alkyl group, optionally substituted with a halogen; and A ” (-) is an anion derived from phosphorus-containing acids, phosphate esters and phosphate amides.

2. The method according to claim 1, wherein A ” (-) is an anion of monoalkyl or dialkyl esters derived from phosphoric acid or phosphorous acid.

3. The method according to claim 1, wherein the compound is selected from S-methylisothiourea methyl phosphite; S-methylisothiourea dimethyl phosphate; S-ethylisothiourea metaphosphate; S-ethylisothiourea ethyl phosphite; S-ethylisothiourea diethyl phosphate; S-propylisothiourea propyl phosphite; S-isopropylisothiourea metaphosphate; S-isopropylisothiourea isopropyl phosphite; S-butylisothiourea dibutyl phosphate; and S-isobutylisothiourea isobutyl phosphite.

4. The method according to claim 3, wherein the compound is S-ethylisothiourea diethyl phosphate.

5. The method according to any one of claims 1 to 4, wherein the endometriosis is selected from ectopic endometriosis, endometrioma, adenomyosis, endometriotic nodules on the uterosacral ligament, and other endometriotic nodules other than those on the uterosacral ligament.

6. The method according to any one of claims 1 to 5, wherein the pharmaceutical composition is administered via a route selected from oral administration, vaginal administration, cervical administration, intrauterine administration, intraperitoneal administration, and intralesional administration.

7. The method of claim 6, wherein the pharmaceutical composition is administered orally.

8. The method according to any one of claims 1 to 7, wherein the pharmaceutical composition is formulated in a form selected from tablets, capsules, solutions, suspensions, emulsions, powders, liquids, gels, syrups, pastes, powders, vaginal suppositories, vaginal rings, vaginal pessaries, vaginal tampons, implants, medicated intrauterine devices, sprays, creams, gels, ointments, and sustained-release formulations.

9. The method according to any one of claims 1 to 8, wherein the pharmaceutical composition is administered daily before menstruation, during menstruation, or both.

10. The method of claim 9, wherein the pharmaceutical composition is administered daily for 2 to 7 days before menstruation and during menstruation.

11. The method of claim 9, wherein the pharmaceutical composition is administered daily for two days before menstruation and during menstruation.

12. The method according to any one of claims 1 to 8, wherein the pharmaceutical composition is administered daily for 11 to 17 consecutive days beginning on day 18 to day 23 of the menstrual cycle.

13. The method according to any one of claims 1 to 8, wherein the pharmaceutical composition is applied daily from day 21 of the menstrual cycle and during menstruation.

14. The method according to any one of claims 1 to 8, wherein the pharmaceutical composition is administered daily for 14 consecutive days.

15. The method according to any one of claims 1 to 8, wherein the pharmaceutical composition is administered daily after laparoscopic surgery or removal of endometriosis tissue to prevent recurrence of endometriosis.

16. The method according to any one of claims 1 to 8, wherein the administration of the pharmaceutical composition prevents or reduces endometrial cell proliferation, migration and / or infiltration to external sites of the uterus.

17. The method according to any one of claims 1 to 8, wherein the administration of the pharmaceutical composition prevents or reduces the proliferation, migration and / or infiltration of endometrial cells into the uterine wall (myometrium).

18. The method according to any one of claims 1 to 17, wherein the therapeutically effective amount of said compound ranges from 1 mg to 400 mg per day.

19. The method of claim 18, wherein the therapeutically effective dose is 50 mg to 100 mg per day.

20. A pharmaceutical composition comprising a compound of formula I as an active agent: in R ” It is a straight-chain or branched alkyl group, optionally substituted with a halogen; and A " (-) is an anion derived from phosphorus-containing acids, phosphate esters and phosphate amides, and the pharmaceutical composition is used to treat endometriosis or prevent recurrence of endometriosis.

21. The pharmaceutical composition according to claim 20, wherein the anion of the compound of formula I is derived from a monoalkyl or dialkyl ester of phosphoric acid or phosphorous acid.

22. The pharmaceutical composition of claim 20, wherein the compound is selected from S-methylisothiourea methyl phosphite; S-methylisothiourea dimethyl phosphate; S-ethylisothiourea metaphosphate; S-ethylisothiourea ethyl phosphite; S-ethylisothiourea diethyl phosphate; S-propylisothiourea propyl phosphite; S-isopropylisothiourea metaphosphate; S-isopropylisothiourea isopropyl phosphite; S-butylisothiourea dibutyl phosphate; and S-isobutylisothiourea isobutyl phosphite.

23. The pharmaceutical composition according to claim 22, wherein the compound is S-ethylisothiourea diethyl phosphate.

24. The pharmaceutical composition of claim 20, wherein the endometriosis is selected from ectopic endometriosis, endometrioma, adenomyosis, endometriotic nodules on the uterosacral ligament, and other endometriotic nodules other than those on the uterosacral ligament.

25. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is administered orally, vaginally, cervix, intrauterinely, intraperitoneally, or intralesionally.

26. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is formulated in a form selected from tablets, capsules, solutions, suspensions, emulsions, powders, liquids, gels, syrups, pastes, powders, vaginal suppositories, vaginal rings, vaginal pessaries, vaginal tampons, implants, medicated intrauterine devices, sprays, creams, gels, ointments, and sustained-release formulations.

27. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is administered daily before, during, or both of menstruation.

28. The pharmaceutical composition of claim 27, wherein the pharmaceutical composition is applied daily from 2 to 7 days before menstruation and during menstruation.

29. The pharmaceutical composition according to any one of claims 20 to 26, wherein the pharmaceutical composition is administered daily for 11 to 17 consecutive days beginning on day 18 to day 23 of the menstrual cycle.

30. The pharmaceutical composition according to any one of claims 20 to 26, wherein the pharmaceutical composition is applied daily from day 21 of the menstrual cycle and during menstruation.

31. The pharmaceutical composition according to any one of claims 20 to 26, wherein the pharmaceutical composition is administered daily for 14 consecutive days.

32. The pharmaceutical composition according to any one of claims 20 to 26, wherein the pharmaceutical composition is administered daily after laparoscopic surgery or removal of endometriosis tissue to prevent recurrence of endometriosis.

33. The pharmaceutical composition according to any one of claims 20 to 26, wherein the administration of the pharmaceutical composition prevents or reduces endometrial cell proliferation, migration and / or infiltration to external sites of the uterus.

34. The pharmaceutical composition according to any one of claims 20 to 26, wherein the administration of the pharmaceutical composition prevents or reduces the proliferation, migration and / or infiltration of endometrial cells into the uterine wall (myometrium).

35. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is administered to a woman in a therapeutically effective amount to treat or prevent recurrence of endometriosis.

36. The pharmaceutical composition according to claim 35, wherein the therapeutically effective amount of said compound ranges from 1 mg to 400 mg per day.

37. The pharmaceutical composition according to claim 35, wherein the therapeutically effective amount is 50 mg to 100 mg per day.

38. A method for treating a woman with endometriosis while preserving her fertility, the method comprising a compound of formula I as an active agent, by administering a therapeutically effective amount of a pharmaceutical composition to increase the probability of conception: in R ” It is a straight-chain or branched alkyl group, optionally substituted with a halogen; and A ” (-) is an anion derived from phosphorus-containing acids, phosphate esters and phosphate amides.